It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug

Frontiers in Microbiology

Volumn 3, Issue AUG, 2012, Pages

  Mesa Arango, Ana C ^a,b   Scorzoni, Liliana ^a,c   Zaragoza, Oscar ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Amphotericin B; Fungal infection; Immunomodulation; Oxidative damage; Pore

Indexed keywords

EID: 84875503043     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2012.00286     Document Type: Article

References (133)

1. Al-Dhaheri, R. S., and Douglas, L. J. (2010). Apoptosis in Candida biofilms exposed to amphotericin B. J. Med. Microbiol. 59, 149-157.
2. Arana, D. M., Nombela, C., and Pla, J. (2010). Fluconazole at subin-hibitory concentrations induces the oxidative-and nitrosative-responsive genes TRR1, GRE2 and YHB1, and enhances the resistance of Candida albicans to phagocytes. J. Antimicrob. Chemother. 65, 54-62.
3. Arning, M., Kliche, K. O., Heer-Sonderhoff, A. H., and Wehmeier, A. (1995). Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38, 459-465.
4. Barker, K. S., Crisp, S., Wiederhold, N., Lewis, R. E., Bareither, B., Eckstein, J., Barbuch, R., Bard, M., and Rogers, P. D. (2004). Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J. Antimicrob. Chemother. 54, 376-385.
5. Becker, M. J., De Marie, S., Fens, M. H., Verbrugh, H. A., and Bakker-Woudenberg, I. A. (2003). Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis. J. Antimicrob. Chemother. 52, 428-434.
6. Bellocchio, S., Gaziano, R., Bozza, S., Rossi, G., Montagnoli, C., Perruccio, K., Calvitti, M., Pitzurra, L., and Romani, L. (2005). Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J. Antimicrob. Chemother. 55,214-222.
7. Ben-Ami, R., Lewis, R. E., and Kontoyiannis, D. P. (2008). Immunocompromised hosts: immunopharmacology of modern antifungals. Clin. Infect. Dis. 47, 226-235.
8. Blum, G., Perkhofer, S., Haas, H., Schrettl, M., Wurzner, R., Dierich, M. P., and Lass-Florl, C. (2008). Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob. Agents Chemother. 52, 1553-1555.
9. Bohme, A., and Hoelzer, D. (1996). Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients. Mycoses 39, 419-426.
10. Borden, E. C., and Leonhardt, P. H. (1976). Enhancement of rIn:rCn-induced interferon production by amphotericin B. Antimicrob. Agents Chemother. 9, 551-553.
11. Brajtburg, J., Powderly, W. G., Kobayashi, G. S., and Medoff, G. (1990). Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34, 183-188.
12. Camacho, M., Gerboles, E., Soler, M., and Vila, L. (2004). Modification of prostanoid secretion in endothelial cells by amphotericin B acting synergistically with interleukin-1beta: possible explanation of proinflammatory effects. J. Infect. Dis. 190, 1026-1032.
13. Cenci, E., Mencacci, A., Del Sero, G., Bistoni, F., and Romani, L. (1997). Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. J. Infect. Dis. 176, 217-226.
14. Chandrasekar, P. (2008). Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate. Ther. Clin. Risk Manag. 4, 1285-1294.
15. Chapman, H. A. Jr., and Hibbs, J. B. Jr. (1978). Modulation of macrophage tumoricidal capability by polyene antibiotics: support for membrane lipid as a regulatory determinant of macrophage function. Proc. Natl. Acad. Sci. U.S.A. 75, 4349-4353.
16. Chattopadhyay, A., and Jafurulla, M. (2011). A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis. Biochem. Biophys. Res. Commun. 416,7-12.
17. Chen, W. C., Chou, D. L., and Feingold, D. S. (1978). Dissociation between ion permeability and the lethal action of polyene antibiotics on Candida albicans. Antimicrob. Agents Chemother. 13, 914-917.
18. Chia, J. K., and McManus, E. J. (1990). In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob. Agents Chemother. 34, 906-908.
19. Choi, J. H., Kwon, E. Y., Park, C. M., Choi, S. M., Lee, D. G., Yoo, J. H., Shin, W. S., and Stevens, D. A. (2010). Immunomodulatory effects of antifungal agents on the response of human monocytic cells to Aspergillus fumigatus conidia. Med. Mycol. 48, 704-709.
20. Cleary, J. D., Chapman, S. W., and Nolan, R. L. (1992). Pharmacologic modulation of inter leukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob. Agents Chemother. 36,977-981.
21. Cohen, B. E. (1992). A sequential mechanism for the formation of aqueous channels by amphotericin B in liposomes. The effect of sterols and phospholipid composition. Biochim. Biophys. Acta 1108, 49-58.
22. Cohen, B. E. (2010). Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects. J. Membr. Biol. 238, 1-20.
23. Cohen, B. E., Benaim, G., Ruiz, M. C., and Michelangeli, F. (1990). Increased calcium permeability is not responsible for the rapid lethal effects of amphotericin B on Leishmania sp. FEBS Lett. 259, 286-288.
24. Cohen, B. E., and Gamargo, M. (1987). Concentration and time dependence of amphotericin B-induced permeability changes across plasma membrane vesicles from Leishmania sp. Drugs. Exp. Clin. Res. 13, 539-546.
25. Coste, A., Linas, M. D., Cassaing, S., Bernad, J., Chalmeton, S., Seguela, J. P., and Pipy, B. (2002). A sub-inhibitory concentration of amphotericin B enhances candidastatic activity of interferon-gamma-and interleukin-13-treated murine peritoneal macrophages. J. Antimicrob. Chemother. 49,731-740.
26. Cuenca-Estrella, M., Ruiz-Diez, B., Martinez-Suarez, J. V., Monzon, A., and Rodriguez-Tudela, J. L. (1999). Comparative in-vitro activity of voriconazole (UK-109, 496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.J. Antimicrob. Chemother. 43, 149-151.
27. Currie, B., Sanati, H., Ibrahim, A. S., Edwards, J. E. Jr., Casadevall, A., and Ghannoum, M. A. (1995). Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob. Agents Chemother. 39, 1934-1937.
28. Dannaoui, E., Borel, E., Persat, F., Piens, M. A., and Picot, S. (2000). Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J. Med. Microbiol. 49, 601-606.
29. Davis, L. E., and Porter, B. S. (2005). Central nervous system coccidioides immitis infections. Curr. Treat. Options Neurol. 7, 157-165.
30. Drutz, D. J., and Lehrer, R. I. (1978). Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am. J. Med. Sci. 276, 77-92.
31. Dupont, B. (2002). Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother. 49(Suppl. 1), 31-36.
32. Ellis, D. (2002). Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49(Suppl. 1), 7-10.
33. Falk, R., Hacham, M., Nyska, A., Foley, J. F., Domb, A. J., and Polacheck, I. (2005). Induction of interleukin-1beta, tumour necrosis factor-alpha and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan. J. Antimicrob. Chemother. 55, 713-720.
34. Finkelstein, A., and Holz, R. (1973). Aqueous pores created in thin lipid membranes by the polyene antibiotics nystatin and amphotericin B. Membranes 2, 377-408.
35. Gale, E. F. (1974). The release of potassium ions from Candida albicans in the presence of polyene antibiotics. J. Gen. Microbiol. 80,451-465.
36. Gale, E. F., Johnson, A. M., and Kerridge, D. (1977). The effect of aeration and metabolic inhibitors on resistance to amphotericin in starved cultures of Candida albicans. J. Gen. Microbiol. 99, 77-84.
37. Gale, E. F., Johnson, A. M., Kerridge, D., and Koh, T. Y. (1975). Factors affecting the changes in amphotericin sensitivity of Candida albicans during growth. J. Gen. Microbiol. 87, 20-36.
38. Geraghty, P., and Kavanagh, K. (2003). Disruption of mitochondrial function in Candida albicans leads to reduced cellular ergosterol levels and elevated growth in the presence of amphotericin B. Arch. Microbiol. 179, 295-300.
39. Ghannoum, M. A., and Rice, L. B. (1999). Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12, 501-517.
40. Gomez-Lopez, A., Zaragoza, O., Rodriguez-Tudela, J. L., and Cuenca-Estrella, M. (2008). Pharmacotherapy of yeast infections. Expert Opin. Pharmacother. 9, 2801-2816.
41. Gray, K. C., Palacios, D. S., Dailey, I., Endo, M. M., Uno, B. E., Wilcock, B. C., and Burke, M. D. (2012). Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl. Acad. Sci. U.S.A. 109, 2234-2239.
42. Gulati, M., Bajad, S., Singh, S., Ferdous, A. J., and Singh, M. (1998). Development of liposomal amphotericin B formulation. J. Micro encapsul. 15, 137-151.
43. Haido, R. M., and Barreto-Bergter, E. (1989). Amphotericin B-induced damage of Trypanosoma cruzi epimastigotes. Chem. Biol. Interact. 71, 91-103.
44. Hartsel, S. C., Benz, S. K., Ayenew, W., and Bolard, J. (1994). Na+, K+ and Cl-selectivity of the permeability pathways induced through sterol-containing membrane vesicles by amphotericin B and other polyene antibiotics. Eur. Biophys. J. 23, 125-132.
45. Heese-Peck, A., Pichler, H., Zanolari, B., Watanabe, R., Daum, G., and Riezman, H. (2002). Multiple functions of sterols in yeast endocytosis. Mol. Biol. Cell 13, 2664-2680.
46. Hsuchen, C. C., and Feingold, D. S. (1973). Selective membrane toxicity of the polyene antibiotics: studies on natural membranes. Antimicrob. Agents Chemother. 4, 316-319.
47. Janeway, C. J., Traverrs, P., Walport, M., and Shlomchik, M. J. (2005). Immunobiology: The Immune System in Health and Disease. New York, NY: Garland Sciences.
48. Joseph-Horne, T., Loeffler, R. S., Hollomon, D. W., and Kelly, S. L. (1996a). Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. J. Med. Vet. Mycol. 34, 223-225.
49. Joseph-Horne, T., Manning, N., Holoman, D., and Kelly, S. (1996b). Nonsterol related resistance in Ustilago maydis to the polyene antifungals, amphotericin B and nystatin. Phytochemistry 42, 637-639.
50. Kelly, S. L., Lamb, D. C., Kelly, D. E., Loeffler, J., and Einsele, H. (1996). Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348, 1523-1524.
51. Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., and Einsele, H. (1997). Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5, 6-desaturation. FEBS Lett. 400, 80-82.
52. Kelly, S. L., Lamb, D. C., Taylor, M., Corran, A. J., Baldwin, B. C., and Powderly, W. G. (1994). Resistance to amphotericin B associated with defective sterol delta 8->7 iso-merase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol. Lett. 122, 39-42.
53. Khan, Z. U., Al-Sweih, N. A., Ahmad, S., Al-Kazemi, N., Khan, S., Joseph, L., and Chandy, R. (2007). Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole, and fluconazole. J. Clin. Microbiol. 45, 2025-2027.
54. Khot, P. D., Suci, P. A., Miller, R. L., Nelson, R. D., and Tyler, B. J. (2006). A small subpopulation of blastospores in Candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol andbeta-1, 6-glucan pathway genes. Antimicrob. Agents Chemother. 50, 3708-3716.
55. Kim, S. J., and Kwon-Chung, K. J. (1974). Polyene-resistant mutants of Aspergillus fennelliae: sterol content and genetics. Antimicrob. Agents Chemother. 6, 102-113.
56. Kim, S. J., Kwon-Chung, K. J., Milne, G. W., and Prescott, B. (1974). Polyene-resistant mutants of Aspergillus fennelliae: identification of sterols. Antimicrob. Agents Chemother. 6, 405-410.
57. Kinsky, S. C. (1970). Antibiotic interaction with model membranes. Annu. Rev. Pharmacol. 10, 119-142.
58. Kreiner, V. G., Vybornykh, S. N., Baranova, N. A., and Egorov, N. S. (1993). The effect of lovastatin on sterol synthesis and yeast resistance to polyene antibiotics. Antibiot. Khimioter. 38, 16-19.
59. Lamy-Freund, M. T., Ferreira, V. F., and Schreier, S. (1985). Mechanism of inactivation of the polyene antibiotic amphotericin B. Evidence for radical formation in the process of autooxidation. J. Antibiot. (Tokyo) 38, 753-757.
60. Laniado-Laborin, R., and Cabrales-Vargas, M. N. (2009). Amphotericin B: side effects and toxicity. Rev. Iberoam. Micol. 26, 223-227.
61. Lin, Z. Y., Chuang, W. L., and Chuang, Y H. (2009). Amphotericin B up-regulates angiogenic genes in hepatocellular carcinoma cell lines. Eur. J. Clin. Invest. 39, 239-245.
62. Liu, T. T., Lee, R. E., Barker, K. S., Wei, L., Homayouni, R., and Rogers, P. D. (2005). Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob. Agents Chemother. 49, 2226-2236.
63. Lopez-Berestein, G., Fainstein, V., Hopfer, R., Mehta, K., Sullivan, M. P., Keating, M., Rosenblum, M. G., Mehta, R., Luna, M., Hersh, E. M., Reuben, J., Juliano, R. L., and Bodey, G. P. (1985). Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.J. Infect. Dis. 151, 704-710.
64. Louie, A., Baltch, A. L., Franke, M. A., Smith, R. P., and Gordon, M. A. (1994). Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J. Antimicrob. Chemother. 34, 975-987.
65. Louie, A., Baltch, A. L., Smith, R. P., Franke, M. A., Ritz, W. J., Singh, J. K., and Gordon, M. A. (1995). Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of fatal disseminated candidiasis.J. Infect. Dis. 171, 406-415.
66. Merz, W. G., and Sandford, G. R. (1979). Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J. Clin. Microbiol. 9, 677-680.
67. Metcalf, S. C., and Dockrell, D. H. (2007). Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J. Infect. 55, 287-299.
68. Meunier, F., Prentice, H. G., and Ringden, O. (1991). Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28(Suppl.B), 83-91.
69. Mone, Y., Mitta, G., Duval, D., and Gourbal, B. E. (2010). Effect of amphotericin B on the infection success of Schistosoma mansoni in Biomphalaria glabrata. Exp. Parasitol. 125, 70-75.
70. Mouri, R., Konoki, K., Matsumori, N., Oishi, T., and Murata, M. (2008). Complex formation of amphotericin B in sterol-containing membranes as evidenced by surface plasmon resonance. Biochemistry 47,7807-7815.
71. Mousavi, S. A., and Robson, G. D. (2004). Oxidative and amphotericin B-mediated cell death in the opportunistic pathogen Aspergillus fumigatus is associated with an apoptotic-like phenotype. Microbiology 150, 1937-1945.
72. Mowat, E., Lang, S., Williams, C., Mcculloch, E., Jones, B., and Ramage, G. (2008). Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J. Antimicrob. Chemother. 62, 1281-1284.
73. Mozaffarian, N., Berman, J. W., and Casadevall, A. (1997). Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob. Agents Chemother. 41, 1825-1829.
74. Muhammed, M., Coleman, J. J., Carneiro, H. A., and Mylonakis, E. (2011). The challenge of managing fusariosis. Virulence2, 91-96.
75. Nolte, F. S., Parkinson, T., Falconer, D. J., Dix, S., Williams, J., Gilmore, C., Geller, R., and Wingard, J. R. (1997). Isolation and characteriza tion of fluconazole-and ampho tericin B-resistant Candida albi cans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 41, 196-199.
76. Osaka, K., Ritov, V. B., Bernardo, J. E, Branch, R. A., and Kagan, V. E. (1997). Amphotericin pro tects cis-parinaric acid against peroxyl radical-induced oxidation: amphotericin B as an antioxidant. Antimicrob. Agents Chemother. 41, 743-747.
77. Oura, M., Sternberg, T. H., and Wright, E. T. (1955). A new antifungal antibiotic, amphotericin B. Antibiot. Annu. 3, 566-573.
78. Paila, Y D., Saha, B., and Chattopadhyay, A. (2010). Amphotericin B inhibits entry of Leishmania donovani into primary macrophages. Biochem. Biophys. Res. Commun. 399, 429-433.
79. Palacios, D. S., Anderson, T. M., and Burke, M. D. (2007). A post-PKS oxidation of the amphotericin B skeleton predicted to be critical for channel formation is not required for potent antifungal activity. J. Am. Chem. Soc. 129, 13804-13805.
80. Palacios, D. S., Dailey, I., Siebert, D. M., Wilcock, B. C., and Burke, M. D. (2011). Synthesis-enabled functional group deletions reveal key underpinnings of amphotericin B ion channel and antifungal activities. Proc. Natl. Acad. Sci. U.S.A. 108, 6733-6738.
81. Phillips, A. J., Sudbery, I., and Ramsdale, M. (2003). Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc. Natl. Acad. Sci. U.S.A. 100, 14327-14332.
82. Pleskoff, O., Seman, M., and Alizon, M. (1995). Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus-cell fusion but not on cell-cell fusion. J. Virol. 69, 570-574.
83. Powderly, W. G., Kobayashi, G. S., Herzig, G. P., and Medoff, G. (1988). Amphotericin B-resistantyeast infection in severely immuno-compromised patients. Am. J. Med. 84, 826-832.
84. Puccetti, P., Romani, L., and Bistoni, F. (1995). A TH1-TH2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol. 3, 237-240.
85. Ramos, H., Attias De Murciano, A., Cohen, B. E., and Bolard, J. (1989). The polyene antibiotic amphotericin B acts as a Ca2+ ionophore in sterol-containing liposomes. Biochim. Biophys. Acta 982, 303-306.
86. Ramos, H., Valdivieso, E., Gamargo, M., Dagger, F., and Cohen, B. E. (1996). Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. J. Membr. Biol. 152, 65-75.
87. Reuter, S., Merkle, M., Brehm, K., Kern, P., and Manfras, B. (2003). Effect of amphotericin B on larval growth of Echinococcus multilocularis. Antimicrob. Agents Chemother. 47, 620-625.
88. Ringden, O., Meunier, F., Tollemar, J., Ricci, P., Tura, S., Kuse, E., Viviani, M. A., Gorin, N. C., Klastersky, J., Fenaux, P., Prentice, H. G., and Ksionski, G. (1991). Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 28(Suppl.B), 73-82.
89. Rogasi, P. G., Zanazzi, M., Nocentini, J., Fantoni, E., Trotta, M., Faggi, E., Fontanelli, A., Bertoni, E., Salvadori, M., and Leoncini, F. (2007). Disseminated Scedosporium apiospermum infection in renal transplant recipient: long-term successful treatment with voriconazole: a case report. Transplant. Proc. 39, 2033-2035.
90. Rogers, P. D., Stiles, J. K., Chapman, S. W., and Cleary, J. D. (2000). Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1. J. Infect. Dis. 182, 1280-1283.
91. Roilides, E., Lyman, C. A., Filioti, J., Akpogheneta, O., Sein, T., Lamaignere, C. G., Petraitiene, R., and Walsh, T. J. (2002). Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and poly-morphonuclear leukocytes against Aspergillus fumigatus. Antimicrob. Agents Chemother. 46, 1974-1976.
92. Romani, L., and Howard, D. H. (1995). Mechanisms of resistance to fungal infections. Curr. Opin. Immunol. 7, 517-523.
93. Romero, E. A., Valdivieso, E., and Cohen, B. E. (2009). Formation of two different types of ion channels by amphotericin B in human erythrocyte membranes. J. Membr. Biol. 230, 69-81.
94. Rust, D. M., and Jameson, G. (1998). The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice. Oncol. Nurs. Forum 25, 35-48.
95. Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D., and Dismukes, W. E. (2000). Practice guidelines for the management of cryptococcal disease. Infectious diseases society of america. Clin. Infect. Dis. 30, 710-718.
96. Sabra, R., and Branch, R. A. (1990). Amphotericin B nephrotoxicity. DrugSaf. 5,94-108.
97. Safe, L. M., Safe, S. H., Subden, R. E., and Morris, D. C. (1977). Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis. Can. J. Microbiol. 23, 398-401.
98. Saliba, F., and Dupont, B. (2008). Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med. Mycol. 46,97-112.
99. Sangalli-Leite, F., Scorzoni, L., Mesa-Arango, A. C., Casas, C., Herrero, E., Gianinni, M. J., Rodriguez-Tudela, J. L., Cuenca-Estrella, M., and Zaragoza, O. (2011). Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst. Microbes Infect. 13, 457-467.
100. Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., and Bille, J. (2003). Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob. Agents Chemother. 47, 2404-2412.
101. Sau, K., Mambula, S. S., Latz, E., Henneke, P., Golenbock, D. T., and Levitz, S. M. (2003). The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor-and CD14-dependent mechanism. J. Biol. Chem. 278, 37561-37568.
102. Saxena, S., Bhatnagar, P. K., Ghosh, P. C., and Sarma, P. U. (1999). Effect of amphotericin B lipid formulation on immune response in aspergillosis. Int. J. Pharm. 188, 19-30.
103. Sculier, J. P., and Body, J. J. (1991). Intravenous administration of amphotericin B entrapped in liposomes: induction of high serum levels of TNF alpha. Ann. Oncol. 2, 141-144.
104. Shadkchan, Y., Keisari, Y., and Segal, E. (2004). Cytokines in mice treated with amphotericin B-intralipid. Med. Mycol. 42, 123-128.
105. Sharma, M., Manoharlal, R., Negi, A. S., and Prasad, R. (2010). Synergistic anticandidal activity of pure polyphenol curcumin I in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis. FEMS Yeast Res. 10, 570-578.
106. Shoham, S., Huang, C., Chen, J. M., Golenbock, D. T., and Levitz, S. M. (2001). Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysac-charide capsule. J. Immunol. 166, 4620-4626.
107. Simitsopoulou, M., and Roilides, E. (2005). Evaluation of immunotherapy in invasive candidiasis: antifungal activity and cytokine expression assays. Methods Mol. Med. 118, 161-179.
108. Simitsopoulou, M., Roilides, E., Dotis, J., Dalakiouridou, M., Dudkova, F., Andreadou, E., and Walsh, T. J. (2005). Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob. Agents Chemother. 49, 1397-1403.
109. Sokol-Anderson, M., Sligh, J. E. Jr., Elberg, S., Brajtburg, J., Kobayashi, G. S., and Medoff, G. (1988). Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob. Agents Chemother. 32, 702-705.
110. Sokol-Anderson, M. L., Brajtburg, J., and Medoff, G. (1986). Amphotericin B-induced oxidative damage and killing of Candida albicans. J. Infect. Dis. 154, 76-83.
111. Sud, I. J., and Feingold, D. S. (1983). Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans. Antimicrob. Agents Chemother. 23, 185-187.
112. Sullivan, G. W., Carper, H. T., and Mandell, G. L. (1992). Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended preparation of amphotericin B (Fungizone). Antimicrob. Agents Chemother. 36, 39-45.
113. Suschek, C. V., Bonmann, E., Kapsokefalou, A., Hemmrich, K., Kleinert, H., Forstermann, U., Kroncke, K. D., Mahotka, C., and Kolb-Bachofen, V. (2002). Revisiting an old antimicrobial drug: amphotericin B induces interleukin-1-converting enzyme as the main factor for inducible nitricoxide synthase expression in activated endothelia. Mol. Pharmacol. 62, 936-946.
114. Suschek, C. V., Bonmann, E., Kleinert, H., Wenzel, M., Mahotka, C., Kolb, H., Forstermann, U., Gerharz, C. D., and Kolb-Bachofen, V. (2000). Amphotericin B severely affects expression and activity of the endothelial constitutive nitric oxide synthase involving altered mRNA stability. Br. J. Pharmacol. 131, 473-481.
115. Sutton, D. A., Sanche, S. E., Revankar, S. G., Fothergill, A. W., and Rinaldi, M. G. (1999). In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J. Clin. Microbiol. 37, 2343-2345.
116. Te Welscher, Y. M., Jones, L., Van Leeuwen, M. R., Dijksterhuis, J., De Kruijff, B., Eitzen, G., and Breukink, E. (2010). Natamycin inhibits vacuole fusion at the priming phase via a specific interaction with ergosterol. Antimicrob. Agents Chemother. 54, 2618-2625.
117. Tohyama, M., Kawakami, K., and Saito, A. (1996). Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide. Antimicrob. Agents Chemother. 40, 1919-1923.
118. Torrado, J. J., Espada, R., Ballesteros, M. P., and Torrado-Santiago, S. (2008). Amphotericin B formulations and drug targeting. J. Pharm. Sci. 97, 2405-2425.
119. Trajkovic, V., Markovic, M., Samardzic, T., Miljkovic, D. J., Popadic, D., and Mostarica Stojkovic, M. (2001). Amphotericin B potentiates the activation of inducible nitric oxide synthase and causes nitric oxide-dependent mitochondrial dysfunction in cytokine-treated rodent astrocytes. Glia 35, 180-188.
120. Trejo, W. H., and Bennett, R. E. (1963). Streptomyces nodosus sp. n., the amphotericin-producing organism. J. Bacteriol. 85, 436-439.
121. Turtinen, L. W., Prall, D. N., Bremer, L. A., Nauss, R. E., and Hartsel, S. C. (2004). Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations. Antimicrob. Agents Chemother. 48, 396-403.
122. Vandeputte, P., Tronchin, G., Berges, T., Hennequin, C., Chabasse, D., and Bouchara, J. P. (2007). Reduced susceptibility to polyenes associated with a missense mutation inthe ERG6 gene in a clinical isolate of Candida glabrata with pseudo-hyphal growth. Antimicrob. Agents Chemother. 51,982-990.
123. Vazquez, J. A., Arganoza, M. T., Boikov, D., Yoon, S., Sobel, J. D., and Akins, R. A. (1998). Stable pheno-typic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles. J. Clin. Microbiol. 36, 2690-2695.
124. Veerareddy, P. R., and Vobalaboina, V. (2004). Lipid-based formulations of amphotericin B. Drugs Today (Barc) 40, 133-145.
125. Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., Dinubile, M. J., Reboli, A., Bow, E., Lister, J., and Anaissie, E. J. (1998). Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 26, 1383-1396.
126. Walsh, T. J., Petraitis, V., Petraitiene, R., Field-Ridley, A., Sutton, D., Ghannoum, M., Sein, T., Schaufele, R., Peter, J., Bacher, J., Casler, H., Armstrong, D., Espinel-Ingroff, A., Rinaldi, M. G., and Lyman, C.A. (2003). Experimental pul monary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188, 305-319.
127. Waness, A., Dawsari, G. A., and Jahdali, H. A. (2009). The rise of an oppurtunistic infection called Invasive Zygomycosis. J. Glob. Infect. Dis. 1, 131-138.
128. Wilson, E., Thorson, L., and Speert, D. P. (1991). Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob. Agents Chemother. 35, 796-800.
129. Wolf, J. E., and Massof, S. E. (1990). In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect. Immun. 58, 1296-1300.
130. Woods, R. A., Bard, M., Jackson, I. E., and Drutz, D. J. (1974). Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria. J. Infect. Dis. 129, 53-58.
131. Yano, T., Itoh, Y., Kawamura, E., Maeda, A., Egashira, N., Nishida, M., Kurose, H., and Oishi, R. (2009). Amphotericin B-induced renal tubular cell injury is mediated by Na+ Influx through ion-permeable pores and subsequent activation of mitogen-activated protein kinases and elevation of intracellular Ca2+ concentration. Antimicrob. Agents Chemother. 53, 1420-1426.
132. Yardley, V., and Croft, S. L. (1999). In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am. J. Trop. Med. Hyg. 61, 193-197.
133. Zhang, Y. Q., Gamarra, S., Garcia-Effron, G., Park, S., Perlin, D. S., and Rao, R. (2010). Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs. PLoS Pathog. 6:e1000939. doi: 10.1371/journal.ppat.1000939